logo

For the Inventor, By the Inventor

Little Falls, NJ, United States of America

Hoffmann-La Roche Inc.

USPTO Granted Patents = 5,026

% Expired Patents = 24.0



Trademarks = 58

Forward Citations = 45,311

Loading Chart...
Loading Chart...

3,762 inventors (with patents filed for the assignee):

goldMedal Matthias Heinrich Nettekoven (126 out of 130 patents)

silverMedal Bernd Kuhn (113 out of 118 patents)

bronzeMedal Milan R Uskokovic (113 out of 118 patents)

4.  Christian Klein (104 out of 178 patents)

5.  Emmanuel Pinard (85 out of 91 patents)

6.  Roger David Norcross (83 out of 94 patents)

7.  Georg Jaeschke (82 out of 86 patents)

8.  Perry Rosen (82 out of 87 patents)

9.  Gabriel G Saucy (81 out of 85 patents)

10.  Hasane Ratni (78 out of 91 patents)

11.  Hans Hilpert (77 out of 87 patents)

12.  Werner Neidhart (77 out of 79 patents)

13.  Patrizio Mattei (76 out of 79 patents)

14.  Mark Rogers-Evans (76 out of 85 patents)

15.  Emilio Kyburz (75 out of 75 patents)


Core Competencies:
Oligonucleotides
Bispecific Antibodies
Cancer Treatment
Immunoassays
Autoimmune Disease
Genetic Markers
Machine Learning
Drug Delivery
Protein Engineering
Pharmaceutical Formulations
Ligands
Therapeutics

5,026 patents:

1. 12760032 - Heterocyclic compounds (2026-10-13),
2. 12758544 - Pharmaceutical formulation (2026-10-13),
3. D1151997 - Medical syringe (2026-10-06),
4. 12755384 - Method for analyzing digital images (2026-10-06),
5. 12753175 - Process for the preparation of (9S)-2-bromo-9-(2,3,4-trifluorophenyl)-6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[1,5-A]azepine (2026-10-06),
6. 12751615 - Virtual reality techniques for characterizing visual capabilities (2026-10-06),
7. 12749191 - Multimodal prediction of visual acuity response (2026-09-29),
8. 12747254 - Process for preparing heterocyclic pharmaceutical compounds (2026-09-29),
9. 12747235 - Triazolyl derivatives as GABAα5 PAM (2026-09-29),
10. 12747217 - Process for the manufacture of tetrazole derivatives (2026-09-29),
11. 12742848 - Beacon-based location detection (2026-09-22),
12. 12742785 - High ionic strength dissociation assay for high drug tolerant testing (2026-09-22),
13. 12742003 - Multistep final filtration (2026-09-22),
14. 12741969 - Process for the preparation of 2-bromo-4-(3,5-difluorophenyl)-4,5,6,7-tetrahydro-[1,2,4]triazolo[1,5-a]pyrimidine (2026-09-22),
15. 12741952 - Compounds (2026-09-22),
Company Overview
Hoffmann-La Roche Inc., based in Little Falls, NJ, is a leader in pharmaceutical innovations, focusing on the development of advanced therapies and diagnostics. The company specializes in cutting-edge technologies such as oligonucleotides and bispecific antibodies, targeting critical areas like cancer treatment and autoimmune diseases. With a strong emphasis on genetic markers and machine learning, Roche is committed to enhancing drug delivery systems and improving patient outcomes through innovative solutions in healthcare.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 20 2026

Hoffmann-La Roche Inc. USPTO Patent Assignee Logo
5,026 Patents

#1 in Little Falls, NJ

#5 in New Jersey

#86 in US

#185 in the World

Little Falls, NJ (US)
Little Falls, NJ, United States of America

Hoffmann-La Roche Inc.

Forward Citations = 45,311

3,762 inventors:

goldMedal Matthias Heinrich Nettekoven (126 out of 130 patents)

silverMedal Bernd Kuhn (113 out of 118 patents)

bronzeMedal Milan R Uskokovic (113 out of 118 patents)

4.  Christian Klein (104 out of 178 patents)

5.  Emmanuel Pinard (85 out of 91 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Hoffmann-La Roche Inc.. Retrieved from https://idiyas.com/company/hoffmann-la-roche

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…